Literature DB >> 12874333

DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses.

Dror I Baruch1, Benoit Gamain, Louis H Miller.   

Abstract

The variant surface antigens of Plasmodium falciparum are an important component of naturally acquired immunity and an important vaccine target. However, these proteins appear to elicit primarily variant-specific antibodies. We tested if naked DNA immunization can elicit more cross-reactive antibody responses and allow simultaneous immunization with several variant constructs. Mice immunized with plasmid DNA expressing variant cysteine-rich interdomain region 1 (CIDR1) domains of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) developed antibodies that were reactive to the corresponding PfEMP1s as measured by an enzyme-linked immunosorbent assay, flow cytometry, and agglutination of parasitized erythrocytes (PEs). We observed some cross-reactive immune responses; for example, sera from mice immunized with one domain agglutinated PEs of various lines and recognized heterologous domains expressed on the surface of Chinese hamster ovary (CHO) cells. We found no significant antigenic competition when animals were immunized with a mixture of plasmids or immunized sequentially with individual constructs. Moreover, mixed or sequential immunizations resulted in greater cross-reactive agglutination responses than immunization with a single domain. Recombinant protein (Sc y179) immunization after priming with DNA (prime-boost regimen) increased antibody titers to the homologous domain substantially but seemed to diminish the cross-reactive responses somewhat. The titer of agglutinating antibodies was previously shown to correlate with protection. Surprisingly, the agglutination titers of sera from DNA immunization were high, similar to those of pooled human hyperimmune sera. These sera also appeared to give limited low-titer variant transcending agglutination. Thus, DNA immunization appears to be a very useful tool for developing variant antigen vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874333      PMCID: PMC166004          DOI: 10.1128/IAI.71.8.4536-4543.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  The humoral immune responses elicited in mice by inoculations with a recombinant protein or DNA based on the circumsporozoite-protein gene of Plasmodium falciparum.

Authors:  Z Fang; Y-W Liu; Y-K Shi; X-B Yu; W-Q Huang; X Ji
Journal:  Ann Trop Med Parasitol       Date:  2002-07

2.  Maternal antibodies block malaria.

Authors:  M Fried; F Nosten; A Brockman; B J Brabin; P E Duffy
Journal:  Nature       Date:  1998-10-29       Impact factor: 49.962

3.  Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation.

Authors:  T Fukumoto; N Torigoe; S Kawabata; M Murakami; T Uede; T Nishi; Y Ito; K Sugimura
Journal:  Nat Biotechnol       Date:  1998-03       Impact factor: 54.908

4.  Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence.

Authors:  D I Baruch; X C Ma; H B Singh; X Bi; B L Pasloske; R J Howard
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

5.  Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1.

Authors:  C F Ockenhouse; M Ho; N N Tandon; G A Van Seventer; S Shaw; N J White; G A Jamieson; J D Chulay; H K Webster
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

6.  Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

Authors:  P C Bull; B S Lowe; M Kortok; C S Molyneux; C I Newbold; K Marsh
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

7.  Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation.

Authors:  Lei Zhang; Edward Nolan; Sebastian Kreitschitz; Dietmar P Rabussay
Journal:  Biochim Biophys Acta       Date:  2002-08-15

8.  Plasmodium falciparum: the human agglutinating antibody response to the infected red cell surface is predominantly variant specific.

Authors:  C I Newbold; R Pinches; D J Roberts; K Marsh
Journal:  Exp Parasitol       Date:  1992-11       Impact factor: 2.011

9.  Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta.

Authors:  M Fried; P E Duffy
Journal:  Science       Date:  1996-06-07       Impact factor: 47.728

10.  Age-related buildup of humoral immunity against epitopes for rosette formation and agglutination in African areas of malaria endemicity.

Authors:  A Barragan; P G Kremsner; W Weiss; M Wahlgren; J Carlson
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more
  11 in total

1.  Limited cross-reactivity among domains of the Plasmodium falciparum clone 3D7 erythrocyte membrane protein 1 family.

Authors:  Louise Joergensen; Louise Turner; Pamela Magistrado; Madeleine A Dahlbäck; Lasse S Vestergaard; John P Lusingu; Martha Lemnge; Ali Salanti; Thor G Theander; Anja T R Jensen
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

2.  Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain.

Authors:  Kirsten Moll; Fredrik Pettersson; Anna M Vogt; Cathrine Jonsson; Niloofar Rasti; Sanjay Ahuja; Mats Spångberg; Odile Mercereau-Puijalon; David E Arnot; Mats Wahlgren; Qijun Chen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

3.  Induction of crossreactive antibodies against the Plasmodium falciparum variant protein.

Authors:  Sylvie Gratepanche; Benoit Gamain; Joseph D Smith; Bridget A Robinson; Allan Saul; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

4.  Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA.

Authors:  Marion Avril; Bridget R Kulasekara; Severin O Gose; Chris Rowe; Madeleine Dahlbäck; Patrick E Duffy; Michal Fried; Ali Salanti; Lynda Misher; David L Narum; Joseph D Smith
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

5.  Polymorphism in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its receptor specificity.

Authors:  D C Ghislaine Mayer; Jian-Bing Mu; Osamu Kaneko; Junhui Duan; Xin-zhuan Su; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 6.  Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications.

Authors:  J Alexandra Rowe; Antoine Claessens; Ruth A Corrigan; Mònica Arman
Journal:  Expert Rev Mol Med       Date:  2009-05-26       Impact factor: 5.600

7.  Analysis of antibody induction upon immunization with distinct NTS-DBL1α-domains of PfEMP1 from rosetting Plasmodium falciparum parasites.

Authors:  Davide Angeletti; Letusa Albrecht; Mats Wahlgren; Kirsten Moll
Journal:  Malar J       Date:  2013-01-24       Impact factor: 2.979

8.  Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.

Authors:  Kumari G Lokugamage; Naoko Yoshikawa-Iwata; Naoto Ito; Douglas M Watts; Philip R Wyde; Nan Wang; Patrick Newman; Chien-Te Kent Tseng; C J Peters; Shinji Makino
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

Review 9.  Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates.

Authors:  Jo-Anne Chan; Freya J I Fowkes; James G Beeson
Journal:  Cell Mol Life Sci       Date:  2014-04-02       Impact factor: 9.261

Review 10.  Progress and prospects for blood-stage malaria vaccines.

Authors:  Kazutoyo Miura
Journal:  Expert Rev Vaccines       Date:  2016-02-03       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.